Torigen Pharmaceuticals and Veterinary Management Groups Enter into Preferred Partner Agreement

FARMINGTON, CONN. (PRWEB) APRIL 13, 2023

Torigen Pharmaceuticals, Inc, an animal health biologics company, today announced it has entered into a Preferred Partner Agreement with Veterinary Management Groups (VMG) to provide their more than 2,000 member clinics with access to Torigen’s experimental autologous prescription products and services. This agreement will further expand Torigen’s ability to deliver innovative companion animal cancer treatments to an even greater patient population.

Torigen offers an experimental autologous cancer immunotherapy created from a surgically resected portion of tumor tissue that can be administered by both General Practitioners and Veterinary Oncologists. The combination of Torigen’s innovative products and VMG’s member organizations will allow more clinicians to be part of the veterinary oncology solution for a cancer diagnosis by providing alternative treatment options.

Read the full news release here>>